TapImmune is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. The company’s next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). The company’s off-the-shelf vaccines boost patients’ immune systems to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells, and they are designed to work with 80% of the population.
TapImmune is advancing two clinical stage T-cell vaccine candidates in multiple Phase II and Phase Ib/IIa clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from FDA Fast Track and Orphan Disease Designation. The company is working in collaboration with industry and clinical leaders including Mayo Clinic, Memorial Sloan Kettering Cancer Center, and AstraZeneca.